End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.53 CNY | -0.56% | -2.41% | -34.47% |
May. 24 | China Approves Menovo Pharma's Type 2 Diabetes Drug | MT |
Apr. 29 | Ningbo Menovo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- With a P/E ratio at 11.71 for the current year and 8.82 for next year, earnings multiples are highly attractive compared with competitors.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.47% | 369M | - | ||
+40.73% | 739B | C+ | ||
+31.76% | 598B | B | ||
-6.30% | 353B | C+ | ||
+15.15% | 318B | B- | ||
+4.05% | 285B | C+ | ||
+14.77% | 240B | B+ | ||
+9.53% | 210B | B- | ||
-4.87% | 206B | A+ | ||
+6.17% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 603538 Stock
- Ratings Ningbo Menovo Pharmaceutical Co., Ltd.